Results 11 to 20 of about 832,259 (254)

Soluble factors released by peripheral blood-derived CAR-NK cells cause bystander myeloid cell activation [PDF]

Frontiers in Immunology
IntroductionCAR-T cell therapy is associated with life-threatening inflammatory toxicities, partly due to the activation and secretion of inflammatory cytokines by bystander myeloid cells (BMCs).
Supreet Khanal, Alan Baer, Md Kamal Hossain, Winston Colon-Moran, Santosh Panthi, Nirjal Bhattarai   +5 more
doaj   +2 more sources

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma [PDF]

Journal of Immunology Research, 2017
The chimeric antigen receptor-modified immune effector cell (CAR-T and CAR-NK) therapies are newly developed adoptive treatments of cancers. However, their therapeutic efficacy against solid tumors is limited.
Qing Zhang, Kang Tian, Jinjing Xu, Haixu Zhang, Liantao Li, Qiang Fu, Dafei Chai, Huizhong Li, Junnian Zheng   +8 more
doaj   +2 more sources

CAR-NK cells: A promising cellular immunotherapy for cancer

EBioMedicine, 2020
Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating ...
Guozhu Xie, Han Dong, Yong Liang, James Dongjoo Ham, Romee Rizwan, Jianzhu Chen   +5 more
doaj   +2 more sources

Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression [PDF]

Frontiers in Immunology
Allogeneic natural killer (NK) cell therapy has demonstrated significant potential in cancer immunotherapy by harnessing NK cells to target malignancies.
Dong-Hyeon Jo, Dong-Hyeon Jo, Shelby Kaczmarek, Shelby Kaczmarek, Abrar Ul Haq Khan, Abrar Ul Haq Khan, Jannat Pervin, Jannat Pervin, Diana M. Clark, Suresh Gadde, Suresh Gadde, Suresh Gadde, Lisheng Wang, Lisheng Wang, Lisheng Wang, Scott McComb, Scott McComb, Scott McComb, Scott McComb, Alissa Visram, Alissa Visram, Alissa Visram, Seung-Hwan Lee, Seung-Hwan Lee, Seung-Hwan Lee   +24 more
doaj   +2 more sources

Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models

Journal of Immunology Research, 2018
Adoptive chimeric antigen receptor-modified T or NK cells (CAR-T or CAR-NK) offer new options for cancer treatment. CAR-T therapy has achieved encouraging breakthroughs in the treatment of hematological malignancies.
Qing Zhang, Haixu Zhang, Jiage Ding, Hongyan Liu, Huizhong Li, Hailong Li, Mengmeng Lu, Yangna Miao, Liantao Li, Junnian Zheng   +9 more
doaj   +2 more sources

CAR-NK Engineering to Overcome TME Barriers. [PDF]

Cells
Chimeric antigen receptor (CAR)-based immunotherapy has shown considerable promise in cancer treatment by redirecting immune effector cells to recognize and eliminate tumor cells in an antigen-specific manner.
Islam F, Pupovac A, Boyd RL, Trounson AO.   +3 more
europepmc   +2 more sources

DataSheet_1_ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.pdf

, 2023
IntroductionMetastatic rhabdomyosarcoma (RMS) is a challenging tumor entity that evades conventional treatments and endogenous antitumor immune responses, highlighting the need for novel therapeutic strategies.
Michael Merker, Elise Gradhand, Marian Groot Koerkamp, Frank C. P. Holstege (16486624), Herman Kreyenberg (16848660), Michael T. Meister, Eva Rettinger (3430253), Frank C. P. Holstege, Herman Kreyenberg, Michael Merker (5470025), Torsten Tonn (308943), Laura M. Moser, Winfried S. Wels (358423), Marian Groot Koerkamp (16848669), Catrin Heim, Catrin Heim (9534383), Peter Bader, Jan-Henning Klusmann (12177185), Eva Rettinger, Halvard B. Bonig (16848663), Evelyn Ullrich (5280524), Peter Bader (111174), Elise Gradhand (14901357), Jarno Drost, Jan-Henning Klusmann, Laura M. Moser (9534386), Evelyn Ullrich, Halvard B. Bonig, Torsten Tonn, Michael T. Meister (16848666), Jarno Drost (9261587), Winfried S. Wels   +31 more
core   +1 more source

Increased Activity of a NK-Specific CAR-NK Framework Targeting CD3 and CD5 for T-Cell Leukemias

, 2022
NK effector cells expressing a CAR construct may be used to target T-lineage markers. In this work, we compared the activity of a NK-specific CAR-NK and a CAR-T framework when expressed on NK effector cells to target CD3 and CD5 in T-cell malignancies ...
William G. Telford, Elisaveta Voynova, Jennifer A. Kanakry, Damian Kovalovsky, Francis A. Flomerfelt, Ronald E. Gress, Nga Hawk   +6 more
core   +1 more source

The major advantages and early clinical obstacles of CAR-NK compared to CAR-T cell therapy

, 2023
Chimeric Antigen Receptor T-Cells (CAR-T) are genetically engineered T cells designed to recognize and attack specific cancer cells, thereby offering a targeted approach to cancer immunotherapy. Chimeric Antigen Receptor Natural Killer (CAR-NK) cells are
Chenyang Li
core   +1 more source

Generation of anti-CD19 CAR-NK cells as an allogeneic alternative for B-cell neoplasia treatment

, 2022
Recentemente, a terapia de neoplasias hematológicas foi revolucionada pelo uso de células T autólogas que expressam receptores quiméricos de antígenos (CAR).
Silvestre, Renata Nacasaki
core   +1 more source